Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial

医学 西妥昔单抗 彭布罗利珠单抗 实体瘤疗效评价标准 肿瘤科 临床终点 内科学 人口 头颈部鳞状细胞癌 临床研究阶段 头颈部癌 免疫疗法 临床试验 癌症 结直肠癌 环境卫生
作者
Assuntina Gesualda Sacco,Ruifeng Chen,Francis Paul Worden,Deborah Jean Lee Wong,Douglas R. Adkins,Paul Loren Swiecicki,Wanxing Chai‐Ho,Peter Oppelt,Debanjali Ghosh,Julie Bykowski,Alfredo Molinolo,Emily I. Pittman,Monica Valeria Estrada,Kathryn Ann Gold,Gregory A. Daniels,Scott Michael Lippman,Amanda Natsuhara,Karen S. Messer,Ezra E.W. Cohen
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:22 (6): 883-892 被引量:278
标识
DOI:10.1016/s1470-2045(21)00136-4
摘要

Background Pembrolizumab (PD-1 inhibitor) and cetuximab (EGFR inhibitor) are active as single agents and in combination with cytotoxic chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Given each drug's single agent activity and unique mechanism of action, we aimed to evaluate the anti-tumour activity of PD-1 blockade with EGFR inhibition in recurrent or metastatic HNSCC. Methods This study is an open-label, non-randomised, multi-arm, phase 2 trial done at four academic centres in the USA. Participants were required to have platinum-resistant or platinum-ineligible, recurrent or metastatic HNSCC, be at least 18 years old, have an Eastern Cooperative Oncology Group performance status 0–1, have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and to have received no previous immunotherapy or EGFR inhibition. All participants received pembrolizumab 200 mg intravenously every 3 weeks, combined with an initial loading dose of cetuximab 400 mg/m2 intravenously followed by 250 mg/m2 intravenously weekly (21 day cycle). The primary endpoint was overall response rate defined as the proportion of participants with a partial or complete responses (per RECIST version 1.1) by 6 months in the intention-to-treat population. The safety population included all participants who received at least one dose of pembrolizumab. Herein, the final analysis of cohort 1 (no previous PD-1, PD-L1, or EGFR inhibition for recurrent or metastatic HNSCC) is reported. Three additional cohorts (two for participants with a previous response to immunotherapy followed by relapse or progression, with or without previous cetuximab exposure, and one for cutaneous HNSCC) will be reported separately once fully accrued. This study is registered with ClinicalTrials.gov, NCT03082534, and remains open as the three additional cohorts are actively accruing participants. Findings Between March 22, 2017, and July 16, 2019, 33 participants were enrolled to cohort 1. All 33 participants received at least one dose of pembrolizumab. Median follow-up duration was 7·3 months (IQR 3·9–10·9). By 6 months, the overall response rate was 45% (95% CI 28–62), with 15 of 33 participants achieving a partial response. The most common grade 3–4 treatment-related adverse event was oral mucositis (three [9%] of 33 participants), and serious treatment-related adverse events occurred in five (15%) participants. No treatment-related deaths occurred. Interpretation Pembrolizumab combined with cetuximab shows promising clinical activity for recurrent or metastatic HNSCC, and merits further investigation. Funding Merck Sharp & Dohme.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
传奇3的应助被kurumi采纳,获得10
刚刚
CipherSage的应助被111采纳,获得10
刚刚
1秒前
bkagyin的应助被背后白柏采纳,获得10
1秒前
源宥冰完成签到,获得积分10
1秒前
忘记考红薯了完成签到,获得积分10
1秒前
孔德颍完成签到,获得积分10
1秒前
lzh完成签到,获得积分10
1秒前
attt完成签到 ,获得积分10
1秒前
stopray发布了新的文献求助10
1秒前
1秒前
parny完成签到 ,获得积分10
2秒前
2秒前
2秒前
QDU的应助被NICE采纳,获得10
2秒前
2秒前
石大李克的应助被ale采纳,获得10
2秒前
Hello的应助被爱听歌的八宝粥采纳,获得10
2秒前
冷傲雨竹完成签到,获得积分10
3秒前
wngaoran完成签到,获得积分10
3秒前
1101592875发布了新的文献求助30
4秒前
4秒前
4秒前
慧慧完成签到,获得积分10
4秒前
题西林壁完成签到,获得积分10
4秒前
molihuakai的应助被GX采纳,获得10
4秒前
5秒前
观的完成签到,获得积分20
5秒前
5秒前
5秒前
火星上的柏柳完成签到,获得积分10
5秒前
充电宝的应助被yinxinyi采纳,获得10
6秒前
可爱满天完成签到,获得积分10
6秒前
查文献完成签到,获得积分10
6秒前
6秒前
6秒前
6秒前
哦哦完成签到,获得积分10
6秒前
烟花巷陌完成签到,获得积分10
6秒前
素心完成签到 ,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180713
求助须知:如何正确求助?哪些是违规求助? 9570752
关于积分的说明 21814119
捐赠科研通 7776960
什么是DOI,文献DOI怎么找? 3433298
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479287